Navigation Links
ApoCell's Cancer Predictive Index Helps Oncologists Select the Most,Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented the results of a study conducted by researchers at the University of Chicago and ApoCell at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago in early June. The study showed that ApoCell's advanced pharmacodynamic biomarker assay technology provides reliable predictive data of clinical response. This study showed the benefit of treating aggressive head and neck cancer patients with a combination of targeted molecular drugs.

Cancer treatment is evolving from the use of highly toxic systemic compounds to targeted molecular drugs that are safer and faster acting because they aim only at cancer cell structures and their bio-mechanisms. Pharmacodynamics is an evolving field that encompasses the study of the biochemical and physiological effects of drugs, the mechanisms of drug action and the relationship between drug concentration and biological effect.

ApoCell has developed an analytical tool, the PDx Index(TM) (Pharmaco-Diagnostic Index), which indicates the likelihood of whether a targeted therapy will elicit a clinical response. The predictive index in this study was derived by comparing the biochemical state of a cancer cell receptor that is critical to the process of angiogenesis or vascularization of tumors. This PDx Index(TM) of patients with head and neck cancer showed a direct correlation between the drug regimen and patient response. This new technology is applicable to predicting the clinical outcome of most molecular targeted cancer drugs.

Dr. Darren Davis, ApoCell's President and CEO comments, "We have developed the PDx Index(TM) methodology to give drug developers, clinical investigators and oncologists a quantitative tool to predict effectiveness of cancer drug treatment. Recent research has demonstrated that different individuals respond differently to the same cancer drug therapy.
'"/>




Page: 1 2

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
11. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
Post Your Comments:
(Date:7/14/2014)... July 14, 2014  Medac Pharma, Inc., a ... of new molecules and improving the effectiveness of ... Drug Administration (FDA) has approved Rasuvo™, a subcutaneous ... for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis ... 10 dosage strengths, ranging from 7.5 mg to ...
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... 2014 Patient engagement has become a ... are turning to an assortment of marketing activities ... of this evolving approach to patient engagement, marketers ... engage patients throughout their experiences with a disease ... mapping the patient journey and employing a consumer ...
Breaking Medicine Technology:Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2
... 17 Engineer/pilot/attorney Jon Roberts, PhD, has dozens of ... thwarts piracy in movie theatres, gadgets that track important ... and even an electronic matchmaker that alerts two nearby ... their match. Now, as Chairman and VP R&D ...
... , , WALTHAM, Mass., Nov. 17 ... firms for pharmaceutical and healthcare issues, finds that, driven by ... novel fast acting opioid reformulations, the cancer pain drug market ... in 2018 in the United States, France, Germany, Italy, Spain, ...
Cached Medicine Technology:When Viruses (Including H1N1) and Bacteria are as Close as your Fingertips; VirWall's New Innovation Can Disarm Killer Keyboards 2The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2
(Date:7/14/2014)... New York, NY (PRWEB) July 14, 2014 ... authority Danny Seo and Harris Publications, debuts with a ... The lifestyle magazine looks at living the healthy, ... authoritative voice that covers everything from food, beauty, travel, ... America’s leading guru of green living. , “Instead of ...
(Date:7/14/2014)... According to the Blood Pressure Solution book ... that features a series of new information on high ... this book can help readers understand more about blood pressure. ... and effective methods to control hypertension naturally. ... Vkool, was penned by Ken Burge, a medical researcher and ...
(Date:7/14/2014)... July 14, 2014 Vaginal Mesh ... against seven different pelvic mesh manufacturers in the U.S. ... & Schulte LLC. The federal complaints are pending against ... 2327), American Medical Systems (MDL No. 2325), and C.R. ... there are 58,262 Vaginal Mesh lawsuit claims pending, according ...
(Date:7/14/2014)... TherapySites, the leading ... professionals, announced today its affiliation with the ... This new relationship allows TherapySites to continue ... members, adding exclusive benefits and promotional offers. , ... dedicated to providing online marketing solutions specifically for ...
(Date:7/14/2014)... July 14, 2014 Townsend Security, ... announced its new IBM i (AS/400, iSeries) Two ... (ISVs). As security threats evolve and make passwords ... struggle to modernize their applications and implement two ... makes it easy for ISVs on the IBM ...
Breaking Medicine News(10 mins):Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:TherapySites Partners With the Licensed Professional Counselors Association of North Carolina to Make Online Marketing Available to All Therapists 2Health News:IBM i ISVs Can Now Easily Integrate Mobile-Based Two Factor Authentication to Increase Security of Solutions 2Health News:IBM i ISVs Can Now Easily Integrate Mobile-Based Two Factor Authentication to Increase Security of Solutions 3
... another bout of West Nile, a potentially fatal, mosquito-spread infection. ... Control of the Harris county has said that the situation ... is still a large percentage of people in Houston who ... repellants or going out at night in short-sleeve shirts can ...
... out with the report that with UK leading the group, cancer ... use of new drugs. ,The study termed uptake of ... as well as in New Zealand, Poland, Czech Republic and South ... US were leaders in using new cancer drugs. ,The ...
... forty per cent (37 per cent) of British women and a ... unattractive on holiday as a result of excessive exposure to the ... has been conducted to highlight Sun Awareness Week, which kicks off ... over unsightly sunburn has meant that one in three Brits could ...
... eyes, say experts, who advise frequent short breaks every half ... ,Studies have shown that eyestrain and other vision problems ... people using video display terminals at work, said Kerry Beebe, ... ,The most common symptoms are eyestrain, blurred vision, ...
... the brakes on a racing heartbeat. ... the May 11 issue of Circulation Research how an enzyme ... of the heart's "fight-or-flight" reaction to adrenaline. ,A ... setting the pace of the beating heart, triggering its neighbor ...
... who is on a visit to the US, has ... in Hyderabad, promising to provide all necessary infrastructure. ... the signing of an MoU between Stanford University, the ... Research Institute) in California Thursday. ,Under the ...
Cached Medicine News:Health News:Health Authorities Fear West Nile Season Again in US 2Health News:Britains Complacent Attitude To Uptake Of New Cancer Drugs Revealed 2Health News:Burnt Brits Don't Feel Hot 2Health News:Many Hours on Computer may Harm Eyes 2Health News:Slowing the Racing Heart 2Health News:Reddy Asks Stanford University to Open Hyderabad Campus 2
... TFC Unite Device is the anterior alternative to ... Unite device features the same 70% fenestrations as ... fenestrations is paramount in the formation of new ... Unite system promotes load sharing between the device ...
Steinmann Pins are available in six point styles ranging from 5/64 to 3/16 in. diameters, in standard 9 in. (230 mm) lengths with threaded and smooth tips. Material: DePuy certified stainless steel. ...
... implant is the only approved radiolucent stand-alone ... assessment with the proven reliability of the ... Vista System is constructed of radiolucent, carbon-fiber ... unobstructed radiologic visualization, providing a new level ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Medicine Products: